Results 11 to 20 of about 5,563 (240)

Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors

Molecular Therapy: Oncolytics, 2023
Immunotherapy with bispecific T cell engagers has shown efficacy in patients with hematologic malignancies and uveal melanoma. Antitumor effects of bispecific T cell engagers in most solid tumors are limited due to their short serum half-life and ...
Saru Basnet, Joao M. Santos, Dafne C.A. Quixabeira, James H.A. Clubb, Susanna A.M. Grönberg-Vähä-Koskela, Victor Arias, Santeri Pakola, Tatiana V. Kudling, Camilla Heiniö, Riikka Havunen, Victor Cervera-Carrascon, Suvi Sorsa, Marjukka Anttila, Anna Kanerva, Akseli Hemminki   +14 more
doaj   +4 more sources

A Pronectin™ AXL-targeted first-in-class bispecific T cell engager (pAXLxCD3ε) for ovarian cancer [PDF]

Journal of Translational Medicine, 2023
Background Pronectins™ are a new class of fibronectin-3-domain 14th-derived (14Fn3) antibody mimics that can be engineered as bispecific T cell engager (BTCE) to redirect immune effector cells against cancer.
Caterina Riillo, Nicoletta Polerà, Maria Teresa Di Martino, Giada Juli, Craig A. Hokanson, Tatjana Odineca, Stefania Signorelli, Katia Grillone, Serena Ascrizzi, Antonia Mancuso, Nicoletta Staropoli, Basilio Caparello, Maria Cerra, Giuseppe Nisticò, Pierosandro Tagliaferri, Roberto Crea, Daniele Caracciolo, Pierfrancesco Tassone   +17 more
doaj   +3 more sources

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma [PDF]

Current Oncology
In the past few years, a new promising therapy, called bispecific T-cell engager (TCE), has been developed and is now available in many countries for patients with relapsed or refractory multiple myeloma.
Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard, Richard LeBlanc, Julie Côté, Jean-Samuel Boudreault, Dominic Duquette, Rayan Kaedbey, Marc Lalancette, Frédéric Larose, Anna Nikonova, Michel Pavic, April Shamy, Jean Roy, Michael Sebag, Sabrina Trudel, Jean-Sébastien Claveau   +16 more
doaj   +3 more sources

Cardiovascular toxicities associated with bispecific T-cell engager therapy [PDF]

Journal for ImmunoTherapy of Cancer
Background Bispecific T-cell engagers (BTEs) are novel agents used to treat hematological malignancies. Early trials were underpowered to define cardiovascular adverse events (CVAE) and no large-scale studies systematically examined the CVAEs associated ...
Ahmed Sayed, Malak Munir, Eric H Yang, Daniel Addison, Sarah Khan, Jiwon Kim, Syed Mahmood, Narendranath Epperla, Alexa Meara, Sanam M Ghazi, Mussammat Ferdousi, Satyam Krishan, Adnan Shaaban, Alma Habib, Onaopepo Kola-Kehinde, Patrick Ruz, Sneha Sharma, Stephanie Feldman   +17 more
doaj   +6 more sources

The landscape of bispecific T cell engager in cancer treatment [PDF]

Biomarker Research, 2021
T cell-based immunotherapies have revolutionized treatment paradigms in various cancers, however, limited response rates secondary to lack of significant T-cell infiltration in the tumor site remain a major problem. To address this limitation, strategies
Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu   +4 more
doaj   +3 more sources

Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity

Communications Biology, 2021
Mandrup et al. describe a panel of recombinant albumin fusions, engineered with different affinities to the human neonatal Fc receptor to program the half-life extension of a bispecific (EGFR/CD3) T-cell engager.
Ole A. Mandrup, Sui Ching Ong, Simon Lykkemark, Anders Dinesen, Imke Rudnik-Jansen, Niels Frederik Dagnæs-Hansen, Jan Terje Andersen, Luis Alvarez-Vallina, Kenneth A. Howard   +8 more
doaj   +2 more sources

Activation of distinct antiviral T-cell immunity: A comparison of bi- and trispecific T-cell engager antibodies with a chimeric antigen receptor targeting HBV envelope proteins

Frontiers in Immunology, 2022
Despite the availability of an effective prophylactic vaccine, 820,000 people die annually of hepatitis B virus (HBV)-related liver disease according to WHO.
Bilge Debelec-Butuner, Bilge Debelec-Butuner, Oliver Quitt, Sophia Schreiber, Frank Momburg, Karin Wisskirchen, Karin Wisskirchen, Ulrike Protzer, Ulrike Protzer   +8 more
doaj   +2 more sources

Tumor-penetrating peptide boosts bispecific T-cell engager antitumor efficacy for the pancreatic cancer [PDF]

Frontiers in Immunology
BackgroundOne of the main hurdles in solid tumors to the limited response of immunotherapy is the lack of sufficient T-cell infiltrate. This study aims to construct an iRGD-modified BiTE-directed T-cell therapeutic approach to enhance the treatment ...
Lu Zou, Lu Zou, Jingjing Chen, Jingjing Chen, Xinyuan Bai, Xinyuan Bai, Yingxin Wang, Yingxin Wang, Changchang Lu, Qiaoli Wang, Subiyinuer Tuerhong, Subiyinuer Tuerhong, Mengzhu Li, Qinghua Zheng, Fanyan Meng, Fanyan Meng, Fanyan Meng, Juan Du, Juan Du   +18 more
doaj   +2 more sources

T Cell Receptor-Directed Bispecific T Cell Engager Targeting MHC-Linked NY-ESO-1 for Tumor Immunotherapy [PDF]

Biomedicines
Antibody-based bispecific T cell engagers (TCEs) that redirect T cells to kill tumor cells have shown a promising therapeutic effect on hematologic malignancies. However, tumor-specific targeting is still a challenge for TCEs, impeding the development of
Yiming Li, Wenbin Zhao, Ying Shen, Yingchun Xu, Shuqing Chen, Liqiang Pan   +5 more
doaj   +2 more sources

Supplementary Data from Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager Efficacy

, 2022
Supplementary Data from Visualizing Spatial and Stoichiometric Barriers to Bispecific T-Cell Engager ...
Dan A. Rock (2309449), Kip P. Conner (2054707), Hugo Gonzalez Velozo (15130407), Arja Ray (15130404), Ran You (602464), Jordan Artichoker (15130401), Matthew F. Krummel (15130410)   +6 more
core   +5 more sources